Home/Pipeline/KRSA-028

KRSA-028

Alzheimer's Disease

Pre-clinicalActive

Key Facts

Indication

Alzheimer's Disease

Phase

Pre-clinical

Status

Active

Company

Korsana Biosciences

About Korsana Biosciences

Korsana Biosciences is a private, pre-clinical-stage biotech company targeting neurodegenerative diseases with a novel BBB-penetrant shuttle platform. The company emerged from stealth in February 2026 with $175 million in funding to advance its lead program, KRSA-028, a shuttled monoclonal antibody for Alzheimer's disease. Led by a seasoned team and backed by prominent life science investors, Korsana aims to overcome a fundamental challenge in CNS drug development by enabling effective biologic delivery to the brain.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Alzheimer's Disease

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active